U.S. regulators have approved another drug to treat all forms of hepatitis C that works in as little as eight weeks.
AbbVie’s drug, Mavyret (mav-EH’-rit), was approved Thursday by the Food and Drug Administration for patients without significant cirrhosis who haven’t been treated previously for the liver-destroying virus, plus those with a form of hepatitis who were not cured by a prior treatment.
Mavyret joins two other AbbVie hepatitis C drugs, one from Merck and several from Gilead on the market.
The list price without insurance will range from $26,400 for eight weeks’ treatment to $52,800 for 16 weeks’ treatment.
Hepatitis C affects at least 2.7 million people in U.S. The virus develops slowly over decades and many people don’t realize they are infected until signs of liver damage emerge.
Related Posts
-
Southwest Airlines flight attendants ratify a contract that will raise pay about 33% over 4 years Posted: April 24, 2024 at 2:19 pmFlight attendants at Southwest Airlines have ratified a contract that
Read more » -
Missouri House backs legal shield for weedkiller maker facing thousands of cancer-related lawsuits Posted: at 2:19 pm
The manufacturer of a popular weedkiller won support Wednesday from
Read more » -
Supreme Court appears skeptical that state abortion bans conflict with federal health care law Posted: at 2:18 pm
Conservative Supreme Court justices appeared skeptical Wednesday that state abortion
Read more » -
UnitedHealth says wide swath of patient files may have been taken in Change cyberattack Posted: April 23, 2024 at 3:28 pmUnitedHealth says files with personal information that could cover a
Read more »
Central Valley Biz Blogs
-
BLOG: Happy birthday to Marketplace at El Paseo
Posted: April 12, 2024 at 1:23 pm
Ten years ago this week, Fresno’s fastest-growing shopping center got
Read more » -
BLOG: Fresno EDC’s April 18 real estate forecast a can’t-miss event
Posted: April 10, 2024 at 11:27 am
The Fresno County Economic Development Corporation (EDC) invites you to
Read more »
